Does the media refer more to RLAY or ASND?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.74 beat Ascendis Pharma A/S's score of 0.35 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, RLAY or EXEL?

Exelixis has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relay Therapeutics $15.35M 249.41 -$276.48M -$1.57 N/A Exelixis $2.32B 6.21 $782.57M $3.18 18.29

Does the media refer more to RLAY or EXEL?

In the previous week, Relay Therapeutics and Relay Therapeutics both had 5 articles in the media. Exelixis' average media sentiment score of 0.80 beat Relay Therapeutics' score of 0.74 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or SMMT more profitable?

Relay Therapeutics' return on equity of -42.27% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Summit Therapeutics N/A -168.94% -141.92%

Does the media refer more to RLAY or SMMT?

In the previous week, Summit Therapeutics had 6 more articles in the media than Relay Therapeutics. MarketBeat recorded 11 mentions for Summit Therapeutics and 5 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.74 beat Summit Therapeutics' score of 0.48 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RLAY or BBIO?

In the previous week, BridgeBio Pharma had 9 more articles in the media than Relay Therapeutics. MarketBeat recorded 14 mentions for BridgeBio Pharma and 5 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.74 beat BridgeBio Pharma's score of 0.69 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RLAY or HALO?

In the previous week, Relay Therapeutics and Relay Therapeutics both had 5 articles in the media. Relay Therapeutics' average media sentiment score of 0.74 beat Halozyme Therapeutics' score of 0.66 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Relay Therapeutics (RLAY) Competitors

$17.47 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$17.62 +0.15 (+0.85%)

As of 09/25/2026 07:58 PM Eastern

Compare

RLAY vs. ASND, EXEL, SMMT, BBIO, and HALO

Should you buy Relay Therapeutics stock or one of its competitors? Relay Therapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), Exelixis (EXEL), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Relay Therapeutics (NASDAQ:RLAY) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Ascendis Pharma A/S has a net margin of 70.99% compared to Relay Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Relay Therapeutics currently has a consensus target price of $25.92, suggesting a potential upside of 48.35%. Ascendis Pharma A/S has a consensus target price of $310.75, suggesting a potential upside of 37.74%. Given Relay Therapeutics' higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.74 beat Ascendis Pharma A/S's score of 0.35 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relay Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	249.41	-$276.48M	-$1.57	N/A
Ascendis Pharma A/S	$814.57M	17.28	-$258M	$12.89	17.50

Summary

Ascendis Pharma A/S beats Relay Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Exelixis?

Relay Therapeutics (NASDAQ:RLAY) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Relay Therapeutics presently has a consensus price target of $25.92, suggesting a potential upside of 48.35%. Exelixis has a consensus price target of $50.29, suggesting a potential downside of 13.54%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Exelixis has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	249.41	-$276.48M	-$1.57	N/A
Exelixis	$2.32B	6.21	$782.57M	$3.18	18.29

Exelixis has a net margin of 35.33% compared to Relay Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Exelixis	35.33%	42.17%	31.76%

In the previous week, Relay Therapeutics and Relay Therapeutics both had 5 articles in the media. Exelixis' average media sentiment score of 0.80 beat Relay Therapeutics' score of 0.74 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Summary

Relay Therapeutics and Exelixis tied by winning 8 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Summit Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Relay Therapeutics presently has a consensus target price of $25.92, suggesting a potential upside of 48.35%. Summit Therapeutics has a consensus target price of $25.91, suggesting a potential upside of 65.97%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Summit Therapeutics	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.41

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Relay Therapeutics' return on equity of -42.27% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Summit Therapeutics had 6 more articles in the media than Relay Therapeutics. MarketBeat recorded 11 mentions for Summit Therapeutics and 5 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.74 beat Summit Therapeutics' score of 0.48 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relay Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	249.41	-$276.48M	-$1.57	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Relay Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market.

Summary

Relay Therapeutics beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Relay Therapeutics compare to BridgeBio Pharma?

Relay Therapeutics (NASDAQ:RLAY) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Relay Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	249.41	-$276.48M	-$1.57	N/A
BridgeBio Pharma	$502.08M	25.53	-$724.93M	-$3.57	N/A

Relay Therapeutics currently has a consensus price target of $25.92, suggesting a potential upside of 48.35%. BridgeBio Pharma has a consensus price target of $102.61, suggesting a potential upside of 56.49%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Relay Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, BridgeBio Pharma had 9 more articles in the media than Relay Therapeutics. MarketBeat recorded 14 mentions for BridgeBio Pharma and 5 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.74 beat BridgeBio Pharma's score of 0.69 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Relay Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Summary

Relay Therapeutics beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Halozyme Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Halozyme Therapeutics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	249.41	-$276.48M	-$1.57	N/A
Halozyme Therapeutics	$1.66B	7.77	$316.89M	$3.35	34.00

In the previous week, Relay Therapeutics and Relay Therapeutics both had 5 articles in the media. Relay Therapeutics' average media sentiment score of 0.74 beat Halozyme Therapeutics' score of 0.66 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 24.86% compared to Relay Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Halozyme Therapeutics	24.86%	260.98%	23.91%

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Relay Therapeutics presently has a consensus target price of $25.92, suggesting a potential upside of 48.35%. Halozyme Therapeutics has a consensus target price of $91.20, suggesting a potential downside of 19.93%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Relay Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

Relay Therapeutics and Halozyme Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLAY vs. The Competition

Export

Metric	Relay Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.83B	$3.94B	$7.32B	$13.16B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-11.13	14.22	276.17	25.77
Price / Sales	249.41	1,334.75	671.28	104.86
Price / Cash	N/A	40.88	28.02	35.00
Price / Book	5.34	15.36	10.51	6.36
Net Income	-$276.48M	-$22.83M	$3.51B	$360.40M
7 Day Performance	-3.96%	-3.14%	-1.39%	-1.07%
1 Month Performance	-6.93%	-7.46%	-3.54%	-2.96%
1 Year Performance	237.91%	28.97%	15.03%	4.57%

Relay Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLAY Relay Therapeutics	2.3778 of 5 stars	$17.47 flat	$25.92 +48.3%	+237.9%	$3.83B	$15.35M	N/A	192
ASND Ascendis Pharma A/S	4.8415 of 5 stars	$237.59 +0.4%	$310.75 +30.8%	+17.5%	$14.77B	$814.57M	18.43	1,189	Analyst Downgrade Gap Up
EXEL Exelixis	2.9925 of 5 stars	$57.22 -2.0%	$50.29 -12.1%	+49.0%	$14.46B	$2.32B	17.99	1,077
SMMT Summit Therapeutics	2.6299 of 5 stars	$16.90 -5.3%	$25.91 +53.3%	-25.5%	$14.24B	N/A	N/A	265	Analyst Forecast Gap Up
BBIO BridgeBio Pharma	3.3201 of 5 stars	$66.58 0.0%	$102.61 +54.1%	+31.0%	$13.02B	$502.08M	N/A	839	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLAY) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Competitors

RLAY vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Relay Therapeutics compare to Exelixis?

Summary

How does Relay Therapeutics compare to Summit Therapeutics?

Summary

How does Relay Therapeutics compare to BridgeBio Pharma?

Summary

How does Relay Therapeutics compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relay Therapeutics (RLAY) Competitors

RLAY vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Is RLAY or ASND more profitable?

Do analysts prefer RLAY or ASND?

Does the media refer more to RLAY or ASND?

Which has more risk and volatility, RLAY or ASND?

Do institutionals and insiders hold more shares of RLAY or ASND?

Which has preferable earnings & valuation, RLAY or ASND?

Summary

How does Relay Therapeutics compare to Exelixis?

Do analysts prefer RLAY or EXEL?

Do institutionals & insiders hold more shares of RLAY or EXEL?

Which has stronger valuation & earnings, RLAY or EXEL?

Is RLAY or EXEL more profitable?

Does the media refer more to RLAY or EXEL?

Which has more volatility and risk, RLAY or EXEL?

Summary

How does Relay Therapeutics compare to Summit Therapeutics?

Do analysts recommend RLAY or SMMT?

Do institutionals and insiders have more ownership in RLAY or SMMT?

Is RLAY or SMMT more profitable?

Does the media refer more to RLAY or SMMT?

Which has stronger earnings & valuation, RLAY or SMMT?

Which has more volatility and risk, RLAY or SMMT?

Summary

How does Relay Therapeutics compare to BridgeBio Pharma?

Which has higher valuation & earnings, RLAY or BBIO?

Do analysts recommend RLAY or BBIO?

Is RLAY or BBIO more profitable?

Does the media refer more to RLAY or BBIO?

Do insiders and institutionals have more ownership in RLAY or BBIO?

Which has more risk & volatility, RLAY or BBIO?

Summary

How does Relay Therapeutics compare to Halozyme Therapeutics?

Which has preferable earnings and valuation, RLAY or HALO?

Does the media refer more to RLAY or HALO?

Is RLAY or HALO more profitable?

Do insiders & institutionals hold more shares of RLAY or HALO?

Which has more volatility & risk, RLAY or HALO?

Do analysts recommend RLAY or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools